for early-stage breast cancer, reports Allison W. Kurian, MD. For women with stage 1 or stage 2 breast cancer, rates have dropped from 35 percent to 21 percent in recent years. More oncologists now order genetic profiling of these early-stage tumors, which helps predict which tumors will not recur after treatment (surgery, radiation, and sometimes hormones). Women with these tumors often are able to skip chemo, sparing them grueling side effects.
Source: Bottom Line Personal April 2018 Allison W. Kurian, MD, is associate professor of medicine at Stanford University School of Medicine in Stanford California, and author of a study published in Journal of the National Cancer Institute.
IF YOU LIKE THESE POSTS, PLEASE CONSIDER CLICKING THE DONATION BUTTON ABOVE. THANK YOU!